René Gerolami

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Jordi Bruix, Shukui Qin, Philippe Merle et al. · The Lancet · 2016 · 3.7K citations · Full text

Medicine, Oncology, Pharmacology +8

Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial

Valérie Vilgrain, Héléna Pereira, Eric Assenat et al. · The Lancet Oncology · 2017 · 826 citations

Medicine, Oncology, Radiation Oncology +16

Pig Liver Sausage as a Source of Hepatitis E Virus Transmission to Humans

Philippe Colson, Patrick Borentain, Benjamin Queyriaux et al. · The Journal of Infectious Diseases · 2010 · 651 citations

Life Sciences, Infectious Diseases, Hepatology +14

Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial

Richard S. Finn, Philippe Merle, Alessandro Granito et al. · Journal of Hepatology · 2018 · 353 citations

Medicine, Oncology, Pharmacology +5

Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study

Masatoshi Kudo, Zhenggang Ren, Yabing Guo et al. · The Lancet · 2025 · 251 citations

Medicine, Oncology, Pharmacotherapy +16